Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: In vitro characteristics and absorption mechanism in rats

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 5, 2012, Pages 740-747

  Zhang, Zhiwen ^a   Gao, Fang ^a,b   Bu, Huihui ^a   Xiao, Jisheng ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Candesartan; Lymphatic transport; Oral bioavailability; Solid lipid nanoparticles

Indexed keywords

ABSORPTION MECHANISMS; AQUEOUS SOLUBILITY; CANDESARTAN; ENTEROCYTES; ENTRAPMENT EFFICIENCY; HEART FAILURE; IN-VITRO; LIPOPHILIC DRUGS; LYMPHATIC TRANSPORT; ORAL ABSORPTION; ORAL BIOAVAILABILITY; PHYSICOCHEMICAL PROPERTY; SOLID LIPID NANOPARTICLE (SLN); SPHERICAL PARTICLE; SYSTEMIC CIRCULATION;

BIOCHEMISTRY; LOADING; PHARMACOKINETICS; RATS; SOLUBILITY;

NANOPARTICLES;

CANDESARTAN HEXETIL; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE CELL; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PORTAL VEIN BLOOD FLOW; RAT; STOMACH ABSORPTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CACO-2 CELLS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; LIPIDS; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

RATTUS;

EID: 84862687247     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.08.016     Document Type: Article

References (39)

1. Ross A., Papademetriou V. Candesartan cilexetil in cardiovascular disease. Expert Rev Cardiovasc Ther 2004, 2:829-835.
2. 1) receptor blockers in hypertension. J Hum Hypertens 2000, 14:S73-S86.
3. Meredith P.A. Candesartan cilexetil-a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin 2007, 23:1693-1705.
4. Ostergren J. Candesartan for the treatment of hypertension and heart failure. Expert Opin Pharmacother 2004, 5:1589-1597.
5. McClellan K.J., Goa K.L. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998, 56:847-869.
6. Matsumori A. Assessment of response to candesartan in heart failure in Japan (ARCH-J) study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003, 5:669-677.
7. Schaefer F., van de Walle J., Zurowska A., Gimpel C., van Hoeck K., Drozdz D., et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010, 28:1083-1090.
8. Tamura Y., Kosuga M., Yamashita M., Tomioka S., Sasaki M., Hikita T., et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clin Exp Nephrol 2008, 12:256-263.
9. Trenkwalder P. Effect of candesartan cilexetil on glucose homeostasis. Multicenter study group. Basic Res Cardiol 1998, 93:140-144.
10. Trenkwalder P., Dahl K., Lehtovirta M., Mulder H. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press 1998, 7:170-175.
11. Suzuki H., Kusuyama T., Omori Y., Soda T., Tsunoda F., Sato T., et al. Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction. Int Heart J 2006, 47:715-725.
12. Ketelhut R., Bramlage P. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. Clin Drug Invest 2010, 30:301-311.
13. Preumont N., Unger P., Goldman S., Berkenboom G. Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion. Cardiovasc Drugs Ther 2004, 18:197-202.
14. Murayama S., Hirano T., Sakaue T., Okada K., Ikejiri R., Adachi M. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003, 26:453-458.
15. Nekkanti V., Pillai R., Venkateshwarlu V., Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm Dev Technol 2009, 14:290-298.
16. Nekkanti V., Karatgi P., Prabhu R., Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech 2010, 11:9-17.
17. Li H., Zhao X., Ma Y., Zhai G., Li L., Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009, 133:238-244.
18. Gasco M.R., Gasco P. Nanovector. Nanomedicine (Lond) 2007, 2:955-960.
19. Kheradmandnia S., Vasheghani-Farahani E., Nosrati M., Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed Nanotechnol Biol Med 2010, 6:753-759.
20. Subedi R.K., Kang K.W., Choi H.K. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 2009, 37:508-513.
21. Paliwal R., Rai S., Vaidya B., Khatri K., Goyal A.K., Mishra N., et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed Nanotechnol Biol Med 2009, 5:184-191.
22. Pietzonka P., Rothen-Rutishauser B., Langguth P., Wunderli-Allenspach H., Walter E., Merkle H.P. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to Caco-2 monolayers mimics particle uptake. Pharm Res 2002, 19:595-601.
23. Huh E.C., Hotchkiss A., Brouillette J., Glahn R.P. Carbohydrate fractions from cooked fish promote iron uptake by Caco-2 cells. J Nutr 2004, 134:1681-1689.
24. Kamath A.V., Darling I.M., Morris M.E. Choline uptake in human intestinal Caco-2 cells is carrier-mediated. J Nutr 2003, 133:2607-2611.
25. Roger E., Lagarce F., Garcion E., Benoit J.P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 2009, 140:174-181.
26. Matveev S., Li X., Everson W., Smart E.J. The role of caveolae and caveolin in vesicle dependent and vesicle independent trafficking. Adv Drug Deliv Rev 2001, 49:237-250.
27. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009, 30:3297-3306.
28. Dahan A., Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci 2005, 24:381-388.
29. Lind M.L., Jacobsen J., Holm R., Mullertz A. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci 2008, 35:211-218.
30. Gao F., Zhang Z., Bu H., Huang Y., Gao Z., Shen J., et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release 2011, 149:168-174.
31. Bargoni A., Cavalli R., Caputo O., Fundaro A., Gasco M.R., Zara G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998, 15:745-750.
32. Trevaskis N.L., Charman W.N., Porter C.J.H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008, 60:702-716.
33. Porter C.J., Trevaskis N.L., Charman W.N. Lipids and lipid based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007, 6:231-248.
34. Shimizu M., Wang Q.D., Sjoquist P.O., Ryden L., The angiotensin I.I. AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther 1999, 13:347-353.
35. Sahoo S.K., Parveen S., Panda J.J. The present and future of nanotechnology in human health care. Nanomed Nanotechnol Biol Med 2007, 3:20-31.
36. Koo O.M., Rubinstein I., Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed Nanotechnol Biol Med 2005, 1:193-212.
37. Hughes G.A. Nanostructure-mediated drug delivery. Nanomed Nanotechnol Biol Med 2005, 1:22-30.
38. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med 2010, 6:714-729.
39. Gao X., Wang T., Wu B., Chen J., Chen J., Yue Y., et al. Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. Biochem Biophys Res Commun 2008, 377:35-40.